X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (132) 132
Publication (17) 17
Patent (5) 5
Book / eBook (1) 1
Book Chapter (1) 1
Book Review (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (56) 56
index medicus (42) 42
female (32) 32
oncology (29) 29
hematology (28) 28
animals (25) 25
cd22 (24) 24
mice (24) 24
male (23) 23
aged (19) 19
middle aged (19) 19
immunology (17) 17
rituximab (16) 16
adult (14) 14
antibodies, monoclonal - therapeutic use (13) 13
lymphoma (13) 13
lymphomas (13) 13
treatment outcome (13) 13
non-hodgkins-lymphoma (12) 12
aged, 80 and over (11) 11
antineoplastic agents - therapeutic use (11) 11
article (11) 11
cancer (11) 11
care and treatment (11) 11
cell line, tumor (11) 11
apoptosis (9) 9
b-cells (9) 9
hb22.7 (9) 9
research (9) 9
xenograft model antitumor assays (9) 9
analysis (8) 8
chemotherapy (8) 8
disease-free survival (8) 8
hemic and lymphatic diseases (8) 8
mice, nude (8) 8
monoclonal antibodies (8) 8
signal transduction (8) 8
antibodies, monoclonal - administration & dosage (7) 7
antibodies, monoclonal - immunology (7) 7
antigen receptor (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
b-lymphocytes - immunology (7) 7
flow cytometry (7) 7
immune system diseases (7) 7
leukemia (7) 7
lymphoma, non-hodgkin - therapy (7) 7
receptor (7) 7
sialic acid binding ig-like lectin 2 - immunology (7) 7
thalidomide - analogs & derivatives (7) 7
therapy (7) 7
antitumor-activity (6) 6
cancer research (6) 6
chronic lymphocytic-leukemia (6) 6
clinical trials (6) 6
in-vivo (6) 6
ligand (6) 6
lymphoma, non-hodgkin - immunology (6) 6
non-hodgkin's lymphomas (6) 6
recurrence (6) 6
signal-transduction (6) 6
thalidomide - adverse effects (6) 6
activation (5) 5
antibodies, monoclonal - pharmacology (5) 5
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
bortezomib (5) 5
diseases (5) 5
human necessities (5) 5
hygiene (5) 5
kaplan-meier estimate (5) 5
lenalidomide (5) 5
lymphoma, mantle-cell - drug therapy (5) 5
lymphoma, non-hodgkin - drug therapy (5) 5
medical or veterinary science (5) 5
pharmacology & pharmacy (5) 5
phase-ii (5) 5
preparations for medical, dental, or toilet purposes (5) 5
prospective studies (5) 5
rheumatoid arthritis (5) 5
saporin (5) 5
sialic acid binding ig-like lectin 2 (5) 5
thalidomide - administration & dosage (5) 5
trial (5) 5
adolescent (4) 4
age factors (4) 4
antibodies, monoclonal, murine-derived (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
autoimmune (4) 4
b cells (4) 4
b lymphocyte (4) 4
b-cell lymphoma (4) 4
binding (4) 4
biochemistry (4) 4
biochemistry & molecular biology (4) 4
biomedicine (4) 4
cell adhesion molecules (4) 4
combined modality therapy (4) 4
disease (4) 4
doxorubicin - administration & dosage (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 08/2014, Volume 371, Issue 9, pp. 878 - 879
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 684 - 691
Journal Article
BioDrugs, ISSN 1173-8804, 08/2013, Volume 27, Issue 4, pp. 293 - 293
CD22 is a B-cell-specific transmembrane gly- coprotein found on the surface of most B cells; it modulates B-cell function, survival and apoptosis. CD22 has... 
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 2014, Volume 13, Issue 4, pp. 560 - 564
Abstract Uncompensated autoantibody-mediated red blood cell (RBC) consumption is the hallmark of autoimmune hemolytic anemia (AIHA). Classification of AIHA is... 
Allergy and Immunology | PATHOGENESIS | EFFICACY | RITUXIMAB | REGULATORY T-CELLS | COLD AGGLUTININ DISEASE | IMMUNOLOGY | WARM | Autoimmunity | Hemolytic anemia | Diagnosis | Immunosuppressive agents
Journal Article
OncoImmunology, ISSN 2162-4011, 12/2012, Volume 1, Issue 9, pp. 1469 - 1475
Antibody drug conjugates (ADCs) can deliver potent drugs to cancer cells by employing the specificity of monoclonal antibodies (mAbs). ADCs have demonstrated... 
antibody drug conjugate | saporin | HB22.7 | non-Hodgkin's lymphoma | CD22 | Non-hodgkin's lymphoma | Saporin | Antibody drug conjugate | RECEPTOR | IMMUNOLOGY | CYTOTOXIC ACTIVITY | ANTI-CD22 MONOCLONAL-ANTIBODY | IMMUNOTOXIN RFB4(DSFV)-PE38 BL22 | IN-VITRO | THERAPY | ONCOLOGY | CELL LYMPHOMA | MALIGNANCIES | LEUKEMIA | PHASE-I
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2014, Volume 371, Issue 9, pp. 878 - 879
To the Editor: In their article, Volkow et al. (June 5 issue) 1 state that marijuana may have adverse health effects, particularly on the vulnerable brains of... 
STROKE | MEDICINE, GENERAL & INTERNAL | Marijuana Smoking - adverse effects | Cannabinoids - therapeutic use | Humans | Cerebrovascular system | Marijuana | Stroke | Cannabis | Health risk assessment | Vasoconstriction
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2009, Volume 145, Issue 3, pp. 344 - 349
Journal Article
Journal Article
Leukemia Research, ISSN 0145-2126, 01/2013, Volume 37, Issue 1, pp. 83 - 88
Targeted therapies, such as those using imatinib and rituximab, have revolutionized the treatment of Philadelphia chromosome-positive and CD20-positive acute... 
Drugs | Cell culture | Animal models | Imatinib | Acute lymphatic leukemia | Severe combined immunodeficiency | Toxicity | Ribosomes | Cytotoxicity | CD22 antigen | Xenografts | Monoclonal antibodies | Remission | saporin | Cytotoxic agents | rituximab
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2019, Volume 94, Issue 11, pp. E291 - E294
Journal Article
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 12/2019, Volume 25, Issue 23, pp. 7004 - 7013
Purpose: Based on the potential for ipilimumab (I) to augment T-cell activation, we hypothesize that ipilimumab would augment the efficacy of rituximab (R) in... 
REFRACTORY FOLLICULAR LYMPHOMA | SINGLE-AGENT | MONOTHERAPY | ONCOLOGY | IMMUNOTHERAPY | INDOLENT LYMPHOMA | REGULATORY T-CELLS | LENALIDOMIDE | NON-HODGKIN-LYMPHOMA | OPEN-LABEL | CTLA-4
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1618 - 1618
Abstract Background Survival rates for older pts with advanced HL (aged ≥60 yrs) were historically poor with doxorubicin, bleomycin, vinblastine and... 
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2018, Volume 13, Issue 1, pp. e0190860 - e0190860
Non-Hodgkin lymphoma (NHL) affects over 400,000 people in the United States; its incidence increases with age. Treatment options are numerous and expanding,... 
APOPTOSIS | DISEASES | 2,6-DIMETHOXYSEMIQUINONE | MULTIDISCIPLINARY SCIENCES | WHEAT-GERM EXTRACT | PREVENTION | AVEMAR | TUMOR-CELLS | T-CELL | CANCER | FREE-RADICALS | Care and treatment | Killer cells | Physiological aspects | Non-Hodgkin's lymphomas | Research | Properties | Wheat | Index Medicus
Journal Article
BioDrugs, ISSN 1173-8804, 08/2013, Volume 27, Issue 4, pp. 293 - 304
CD22 is a B-cell-specific transmembrane glycoprotein found on the surface of most B cells; it modulates B-cell function, survival and apoptosis. CD22 has... 
GEMTUZUMAB OZOGAMICIN | PHASE-I/II | INOTUZUMAB OZOGAMICIN | FRACTIONATED RADIOIMMUNOTHERAPY | MONOCLONAL-ANTIBODY | FOLLICULAR LYMPHOMA | IMMUNOLOGY | HUMANIZED ANTI-CD22 ANTIBODY | ONCOLOGY | NON-HODGKINS-LYMPHOMA | PHARMACOLOGY & PHARMACY | PEGYLATED-LIPOSOMAL DOXORUBICIN | HEMATOLOGIC MALIGNANCIES | Leukemia, B-Cell - metabolism | Molecular Targeted Therapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal - adverse effects | Immunotoxins - adverse effects | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Nanoparticles - adverse effects | Lymphocyte Depletion - adverse effects | Leukemia, B-Cell - radiotherapy | Animals | Immunotoxins - therapeutic use | Sialic Acid Binding Ig-like Lectin 2 - metabolism | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nanoparticles - therapeutic use | Leukemia, B-Cell - drug therapy | Drug Delivery Systems - adverse effects | Radioimmunotherapy - adverse effects | Toxicity | Leukemia | Clinical trials | Cytotoxicity | Kinases | Studies | Chemotherapy | Stem cells | Ligands | Drug therapy | Pharmaceutical industry | Autoimmune diseases | Drug dosages
Journal Article
Journal Article
Biologics: Targets and Therapy, ISSN 1177-5475, 2009, Volume 3, pp. 225 - 232
The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in... 
Rituximab | B-cells | Treatment efficacy | Autoimmune | Rheumatoid arthritis | Pathogenesis
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.